Posted on May 10, 2018 by admin
HARTFORD – State Representative Livvy Floren (R-Greenwich, Stamford) voted in favor of a compromise budget plan based on several Republican initiatives on closing day of the 2018 Session, May 9th, 2018.
In recent weeks, House and Senate Republicans put forth two budget proposals for fiscal year 2019. In what would become a successful effort to lead budget negotiations towards fiscal responsibility, and away from tax hikes and reckless spending, Republican Lawmakers secured major victories for the State of Connecticut by laying the foundation for a compromise deal in the final hours of regular session. Specifically, the GOP proposal would provide $16 million for the Retired Teachers’ Healthcare fund and would establish a study to create a sustainable mechanism for future funding of the program. This was something promised to Connecticut educators for years.
The compromise budget restores the Medicare Savings Plan, rejects Governor Malloy’s cuts to education and municipal aid, and because of consistent opposition from Republican lawmakers, avoids electronic highway tolls. Finally, the plan does not include new tax increases, which was critical to earning the support of the delegation. Although Republicans did not gain support from Democratic lawmakers for their proposed union contract reforms, the Delegation believes these issues will be addressed in the near future.
“‘I am a great believer in luck, and I find the harder I work the more of it I have,’” Rep. Floren said, quoting President Thomas Jefferson. “The plan we passed today is not the be-all-end-all of budgets, but it brings us one step closer to economic recovery, and that is a win for the State of Connecticut. Our problems will not solve themselves. We must work hard to resolve them as a state. Assisting our most vulnerable residents, like our seniors, investing in education, and avoiding further tax increases are the priorities that matter to us, and this budget sets those priorities. However, we must keep pushing for more fiscal reforms in the future. We cannot stop here.”
S.B. 543, An Act Concerning Revisions to the State Budget for Fiscal Year 2019 and Deficiency Appropriations for Fiscal Year 201, passed the House and Senate with veto proof majorities and now awaits Governor Malloy’s signature.
Click below to watch Rep. Floren’s comments on the bond bill, H.B. 5590, which passed the House and Senate unanimously shortly before the budget vote.
Click below to watch Rep. Floren on “Meet the Leaders” with David Smith – May 8, 2018.
Posted on May 5, 2018 by admin
Dear Friends and Neighbors,
There are only five days left in the 2018 Session, and we have a lot of work to do. With that said, I am happy to report that we made progress this week in the struggle to provide stability and sustainability to the State of Connecticut.
Revised Fiscal Year 2019 Budget Proposal
On Wednesday, Republican lawmakers released our second balanced budget proposal for FY 2019. Our plan does the following:
Toll Bill Blocked for this Session
After months of Republican opposition, the Speaker of the House has decided not to call for a vote on tolls because he no longer has the votes.
Tolls are just another tax on Connecticut residents, and I do not support their installation. With that said, I have no doubt that the majority party will attempt to revive the toll debate in the future, but we will be ready.
I will keep you updated as these final days of session unfold. Until then, please contact me at (800) 842-1423 or firstname.lastname@example.org if you have any questions or concerns regarding state government.
Rep. Livvy Floren, 149th district
Posted on May 4, 2018 by admin
CT State Rep. Livvy Floren (R-Greenwich, Stamford), member of the legislature’s Insurance and Real Estate Committee, urged her colleagues to vote in favor of H.B. 5384, An Act Concerning Prescription Drug Costs. The bill would provide more transparency to consumers when it comes to the pricing of prescription drugs. Rep. Floren believes this legislation is particularly important due to the evolving landscape of the pharmaceutical industry, and the growing number of mergers and acquisitions.